Acanya is an acne treatment drug owned by Bausch. The drug, which was first authorized for market use on 23 October, 2008, contains Benzoyl Peroxide and Clindamycin Phosphate as its active ingredients.
The generic versions of Acanya are expected to be released after 05 August, 2029. This is due to the expiration of the last patent on 05 August, 2029. The late release date of Acanya's generic indicates the possible existence of a Para IV filing, which allows manufacturers to challenge the validity of the patents of the branded drug.
Acanya is primarily used for the topical treatment of acne vulgaris in patients 12 years or older. The drug can also be used for general acne treatment. The effectiveness of Acanya is largely due to its active ingredients, Benzoyl Peroxide and Clindamycin Phosphate, which have been proven to be effective in treating acne.
Acanya holds a total of 9 patents, with the last one due to expire on 05 August, 2029. These patents primarily concern the drug's topical pharmaceutical formulation, which contains a low concentration of Benzoyl Peroxide in suspension in water and a water-miscible organic solvent. Given the pending expiration date, we can expect Acanya generic versions to hit the market after this date. Below are the details of the patent: